“…In these diseases, metformin corrects the previously increased number of leukocytes, especially in the group of neutrophils, and the effect is considered secondary to its ability to reduce abnormal activation of neutrophils and their adherence to the endothelium (8). Nevertheless, in chronic long-term use for diabetes, treatment with metformin was not associated with significant blood cell count abnormalities (12,13).…”